To further explore the role of MED12 in prostate cancer, we performed a high-throughput RNA-seq gene expression study to evaluate the effect of MED12 knockdown on the cancer-promoting pathways in LNCaP, 22Rv1, and PC3 cells [Fig. 2A, Supplementary Fig. S2 (25)]. This evidence concerns the gene MED12 and prostate cancer.